ArticleJournal of translational medicine2026
Engineered exosomes from umbilical cord mesenchymal stem cells with pPB modification attenuate hepatic fibrosis via hepatic stellate cell targeting.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent therapeutic strategies for hepatic fibrosis remain limited, primarily due to lack of effectively targeting activated hepatic stellate cells (aHSCs) without compromising treatment safety. Although human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) exhibit promising therapeutic potential, their clinical application is constrained by rapid clearance via the mononuclear phagocyte system (MPS) and inadequate target specificity. This study aimed to develop engineered exosomes with enhanced targeting capabilities toward aHSCs through surface modification, thereby improving their anti-fibrotic efficacy. METHODS AND
resultsWe developed an exosomal delivery system modified with a pPB cyclic peptide (hUCMSC-Exos@pPB) using DSPE-PEG-NH2-based nanoengineering to enable specific targeting of aHSCs. The targeting efficiency of hUCMSC-Exos@pPB was assessed via in vivo imaging and immunofluorescence co-localization analysis with α-smooth muscle actin (α-SMA). Biosafety of the hUCMSC-Exos@pPB delivery system was comprehensively evaluated through CCK-8 assays in vitro, hematoxylin and eosin (HE) staining of major organs in experimental animals, and the analysis of liver and kidney function indicators. The anti-liver fibrosis efficacy of hUCMSC-Exos@pPB was evaluated through multiple approaches, including histopathological assessments (HE, Masson, and Sirius red staining), oxidative stress markers (malondialdehyde and NADPH oxidase 4), measurement of liver function parameters (aspartate aminotransferase and alanine aminotransferase), and analysis of fibrogenic protein expression (α-SMA and COL1a1) in vivo and in HSC-T6 cells. Transcriptome RNA sequencing of liver tissue revealed the PI3K-Akt signaling pathway as a pivotal mechanism through which hUCMSC-Exos@pPB exerts its anti-fibrotic effects.
conclusionThrough rational surface engineering with pPB peptide ligands, we developed a novel exosomal nanoplatform that effectively evades clearance by the MPS and achieves targeted delivery to aHSCs. This strategy significantly enhanced the therapeutic efficacy of hUCMSC-Exos against hepatic fibrosis, therey providing a promising translational approach for the precision treatment of chronic liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.